Month: September 2026

Company Advances Development of First U.S. AI Infrastructure Hub,
Executes Its Quantum & AI Systems Strategy

ITASCA, Ill., Sept. 23, 2026 (GLOBE NEWSWIRE) — Quanome Technologies, Inc. (Nasdaq: QNME) (“Quanome” or the “Company”) is advancing its Quantum and AI Systems business through an approximately US$18.8 million purchase agreement for computing infrastructure powered by NVIDIA GPU technology to build its AI cloud business through its subsidiary, XDT Infrastructure I, LLC (“XDT”). The Company entered into the agreement on September 16, 2026, representing an initial step in executing Quanome’s strategy and its planned phased development of XDT.

Through XDT, Quanome aims to give businesses managed access to AI computing capacity to support their development and expansion. Once operational, clients will be able to develop and run AI applications, process complex data and scale their computing capacity without building and managing their own infrastructure. These capabilities are designed to support faster product development, automation and improved business productivity. For Quanome, XDT offers the potential to build recurring revenue from computing services, with further investment intended to align with customer demand, available funding and operational readiness.

Demand for AI computing services is expanding as businesses integrate AI into their operations. The U.S. Census Bureau reported that 17% to 20% of U.S. businesses used AI between December 2025 and May 2026, while 20% to 23% expected to use it in the following six months. This adoption trend reinforces the importance of scalable computing capacity for businesses seeking to develop and deploy AI applications.

Yang Li, Chief Executive Officer of Quanome Technologies, said: “This investment puts Quanome’s commitment to quantum and AI into action. Through XDT, we aim to give more businesses access to advanced AI computing to power their growth. Our priorities are clear: launch our first hub, grow a strong client base and build recurring revenue to deliver long-term shareholder value.”

XDT sits within Quanome’s Quantum and AI Systems strategic stream, alongside the Group’s three other areas of focus: Quantum Life Sciences – Molecular Discovery, Advanced Nuclear, and Quantum-Safe Cybersecurity. It supports Quanome’s broader objective of translating scientific and technological advances into practical applications that enhance industrial productivity and support economic development.

Quanome expects its first U.S. AI infrastructure hub to be operational from Q4 2026, subject to delivery and deployment.

ENDS

Media / Investor Contact
investor@quanometech.com
www.quanometech.com / www.xdt.com

Editors Notes

About Quanome Technologies

Quanome Technologies, Inc. (Nasdaq: QNME) focuses on opportunities across Quantum and AI Systems, Quantum Life Sciences – Molecular Discovery, Advanced Nuclear, and Quantum-Safe Cybersecurity. The Company combines commercial initiatives with the development of a global scientific network through its Global Quantum Council and Scientific Advisory Network. Through its subsidiary “XDT” (XDT Infrastructure I, LLC), Quanome is building an AI cloud business to broaden access to advanced computing resources. www.quanometech.com / www.xdt.com

Forward-Looking Statements

This release contains forward-looking statements regarding the purchase, delivery, deployment and utilization of GPU servers; the expected commencement of operations in Q4 2026; the development and expansion of XDT; and anticipated customer benefits and revenue opportunities. These statements are based on current plans, assumptions and expectations and involve risks and uncertainties. Actual results and timing may differ materially due to financing availability, customer demand, supplier performance, production and delivery conditions, regulatory requirements, technical and operational matters, third-party performance and other transaction conditions. There can be no assurance that the purchase or deployment will be completed as contemplated, that operations will begin on the expected schedule, or that the intended commercial benefits will be achieved. Additional risks are described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

Allowance extends the Company’s patent family covering gesture and proportional-control interaction with digital devices, from consumer electronics and XR to emerging applications in robotics and physical AI

YOKNEAM ILLIT, ISRAEL, Sept. 23, 2026 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced a Notice of Allowance from the China National Intellectual Property Administration (“CNIPA”) for its patent application.

The allowed application, titled “Method and Apparatus for a Gesture Controlled Interface for Wearable Devices,” extends a U.S.-granted intellectual property (“IP”) family covering a wrist-worn band that senses surface nerve conduction signals, the Company’s term for surface electromyography (“EMG”)-class bio-potentials, and turns hand and finger movement into commands without cameras, controllers or touchscreens. The China allowance specifically protects the Company’s technological ability to measure the intensity of a gesture – not just whether fingers were pressed together, but how firmly. This distinction converts a simple on/off motion into smooth, continuous, pressure-based control, much like a dimmer rather than a standard light switch.

The Company sees this capability supporting a broad set of applications across its target markets:

• Consumer electronics, extended reality (“XR”) products, and smart glasses – Intuitive, touchless micro-gesture control, navigation, and interaction with digital overlays from the wrist.
• Robotics and physical AI – An emerging area in which capturing the force and motion an individual applies may help robots learn physical tasks from human demonstration. Because the sensing takes place at the user’s wrist, an individual can be recorded working bare-handed and naturally, without instrumented gloves or force-sensing rigs that alter the way an object is handled.
• Accessibility and healthcare – Device control for users with limited mobility and objective measurements of grip strength and rehabilitation progress which can assist users in daily life as well as in clinics.

“Human intent is grounded in physiology – you can’t scrape it from the internet,” said Guy Wagner, Chief Scientific Officer and co-founder of Wearable Devices. “It lives in the body’s own signals: not just that someone picked something up, but how carefully they held it. That kind of nuance is what makes everyday device control feel natural, and it is also what newer fields such as physical AI will need as machines learn from people. We believe that securing this protection in China – the world’s largest developer, manufacturer and market for robotics and consumer electronics – is an important step for our IP portfolio.”

This allowance sits within a broader IP portfolio that now comprises 14 patent matters across the United States, China, and South Korea, six of which have been granted. With priority dates as early as 2015, this protection runs as late as 2043. Alongside its registered MUDRA trademark, the Company continues to pursue protection across major markets as part of a long-standing IP strategy supporting future licensing and partnership opportunities.

About Wearable Devices Ltd.

Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a growth company pioneering human-computer interaction through its AI-powered neural input touchless technology. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company’s product offerings, including the Mudra Band, Mudra Link, and Mudra Pro, are defining the neural input category both for wrist-worn devices and for brain-computer interfaces. These products enable touch-free, intuitive control of digital devices using gestures across multiple operating systems.

Operating through a dual-channel model of direct-to-consumer sales and enterprise licensing and collaborations, Wearable Devices empowers consumers with stylish, functional wearables for enhanced experiences in gaming, productivity, and XR. In the business sector, the Company provides enterprise partners with advanced input solutions for immersive and interactive environments, from augmented reality/virtual reality/XR to smart environments. By setting the standard for neural input in the XR ecosystem, Wearable Devices is shaping the future of seamless, natural user experiences across some of the world’s fastest-growing tech markets. The ai6 Labs ecosystem accelerates this vision by integrating research, products, and AI breakthroughs. Expanding into Physical AI, the Company’s wearable neural sensing layer enriches human-generated training data for robotics and advanced physical systems.

Wearable Devices’ ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols “WLDS” and “WLDSW,” respectively.

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when we discuss the expected benefits of the allowed patent application, the potential applications of the Company’s technology, that the patent allowance marks an important step in the Company’s IP portfolio, and the Company’s future growth and market opportunities, including potential future licensing and partnership opportunities. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2025, filed on March 12, 2026 and our other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

Michal Efraty
IR@wearabledevices.co.il

Phase III advances development of a modular, reusable, swarm based, precision-strike capability designed for U.S. Special Operations Forces, powered by XTEND’s operating system, XOS.

TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND), a leader in software systems and Physical AI, today announced that it has been awarded Phase III of the U.S. Special Operations Command (USSOCOM) Modular Kinetic Lethal Drone (MKLD) program, advancing the Company’s continued work in precision-strike unmanned systems for U.S. Special Operations Forces. The award is separate from, and follows, XTEND’s recent selection as a top performer in the Close-Quarters Battle segment of Gauntlet II under the U.S. Department of War’s Drone Dominance Program.

The MKLD solution brings together XTEND’s Striker, Scorpio 500 and Scorpio 1000 platforms with a common Ground Control Station and XTEND’s XOS operating system. The program is designed to provide small tactical units with modular, recoverable and reusable precision-strike capabilities across indoor, confined-space, urban and outdoor operational environments.

“Phase III is an important milestone in our continued work with the U.S. Special Operations community,” said Aviv Shapira, CEO and Co-Founder of XTEND. “Our focus is on giving Warfighters adaptable robotic capabilities that extend their reach and effectiveness while shifting risk from the operator to unmanned systems.”

Phase III builds on previous USSOCOM investment, development, testing and operational feedback and will further mature the MKLD capability.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of XOS and the MKLD solution, the anticipated development and maturation of the MKLD capability under Phase III and XTEND’s financial prospects, including that according to the Drone Dominance Program the 10 companies selected for Gauntlet II are finalists for prototype contracts and awards are not guaranteed. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the timing and size of orders from government and defense customers, the availability of government funding, the risk that the MKLD program does not advance beyond Phase III or result in production orders, geopolitical and economic conditions in the United States and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND AI Robotics, Inc. (the “Company”) operates under two distinct business strategies. Through its wholly owned subsidiary XTEND Reality Expansion Ltd. (“XTEND”), the Company develops and sells software and advanced robotic hardware solutions for high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (“XOS”), these solutions are designed to provide autonomy at the edge. Through its wholly owned subsidiary JFB Construction Holdings (“JFB”), the Company operates a commercial and residential real estate construction and development strategy, delivering services including retail corporate buildouts, multifamily developments and luxury residential homes. The Company was formed through the combination of XTEND and JFB, uniting two complementary businesses to pursue shared technology and market opportunities, including applying XTEND’s AI-enabled drone technology to jobsite security, land surveying, building inspections and monitoring on JFB’s real estate projects, and leveraging JFB’s construction expertise to help reduce the cost of XTEND’s U.S. manufacturing expansion.

Contacts

XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

Phase III advances development of a modular, reusable, swarm based, precision-strike capability designed for U.S. Special Operations Forces, powered by XTEND’s operating system, XOS.

TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND), a leader in software systems and Physical AI, today announced that it has been awarded Phase III of the U.S. Special Operations Command (USSOCOM) Modular Kinetic Lethal Drone (MKLD) program, advancing the Company’s continued work in precision-strike unmanned systems for U.S. Special Operations Forces. The award is separate from, and follows, XTEND’s recent selection as a top performer in the Close-Quarters Battle segment of Gauntlet II under the U.S. Department of War’s Drone Dominance Program.

The MKLD solution brings together XTEND’s Striker, Scorpio 500 and Scorpio 1000 platforms with a common Ground Control Station and XTEND’s XOS operating system. The program is designed to provide small tactical units with modular, recoverable and reusable precision-strike capabilities across indoor, confined-space, urban and outdoor operational environments.

“Phase III is an important milestone in our continued work with the U.S. Special Operations community,” said Aviv Shapira, CEO and Co-Founder of XTEND. “Our focus is on giving Warfighters adaptable robotic capabilities that extend their reach and effectiveness while shifting risk from the operator to unmanned systems.”

Phase III builds on previous USSOCOM investment, development, testing and operational feedback and will further mature the MKLD capability.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of XOS and the MKLD solution, the anticipated development and maturation of the MKLD capability under Phase III and XTEND’s financial prospects, including that according to the Drone Dominance Program the 10 companies selected for Gauntlet II are finalists for prototype contracts and awards are not guaranteed. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the timing and size of orders from government and defense customers, the availability of government funding, the risk that the MKLD program does not advance beyond Phase III or result in production orders, geopolitical and economic conditions in the United States and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND AI Robotics, Inc. (the “Company”) operates under two distinct business strategies. Through its wholly owned subsidiary XTEND Reality Expansion Ltd. (“XTEND”), the Company develops and sells software and advanced robotic hardware solutions for high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (“XOS”), these solutions are designed to provide autonomy at the edge. Through its wholly owned subsidiary JFB Construction Holdings (“JFB”), the Company operates a commercial and residential real estate construction and development strategy, delivering services including retail corporate buildouts, multifamily developments and luxury residential homes. The Company was formed through the combination of XTEND and JFB, uniting two complementary businesses to pursue shared technology and market opportunities, including applying XTEND’s AI-enabled drone technology to jobsite security, land surveying, building inspections and monitoring on JFB’s real estate projects, and leveraging JFB’s construction expertise to help reduce the cost of XTEND’s U.S. manufacturing expansion.

Contacts

XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders

TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND).

As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide (“PEA”), NeuroThera’s proprietary technology.

The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders.

These U.S. patent applications build on previously announced intellectual property generated through the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.

The continued maturation of the patent portfolio reflects the broader potential applications of NeuroThera’s PEA technology when combined with psychoactive compounds such as psychedelic compounds. NeuroThera believes that these combinations may support the development of novel therapeutic approaches across multiple neuropsychiatric and substance use disorder indications.

NeuroThera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions. The companies remain focused on combining PEA with psychedelic‑derived compounds, while enhancing the intellectual property portfolio supporting these innovative therapeutic programs

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential therapeutic uses of NeuroThera’s product candidates across a range of indications, the broader potential applications of NeuroThera’s PEA technology, the potential of NeuroThera and Clearmind to bring safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions, and continued enhancement of the intellectual property portfolio supporting these innovative therapeutics.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

Latest prepayment continues Holley’s deleveraging trajectory for the last three years and reinforces the Company’s long-term goal to be at or below 3.0x leverage

NASHVILLE, Tenn., Sept. 23, 2026 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced a voluntary prepayment of $10 million toward its term loan, reflecting the Company’s continued focus on balance sheet optimization and disciplined capital deployment.

Including this latest payment, Holley has repaid a total of $125 million of debt since September 2023, funded entirely through free cash flow generation. Since initiating this program, the Company has reduced its Total Leverage Ratio from a peak of 5.67x, remains on track to reach its previously communicated year-end target of below 3.5x, and continues to target a long-term leverage ratio of approximately 3.0x. Cumulatively, the $125 million in debt reductions generate approximately $5 million in annualized net interest savings.

“This latest prepayment reflects the discipline and consistency of our capital allocation approach,” said Jesse Weaver, Chief Financial Officer of Holley Performance Brands. “Since 2023, we have reduced our debt by $125 million, funded entirely by free cash flow, while continuing to invest in the business. That progress reflects our three-pronged capital allocation framework: reducing leverage, pursuing accretive M&A, and returning capital to shareholders opportunistically. We remain on track to bring year-end leverage below 3.5x, with a long-term target of approximately 3.0x, and we believe this continued financial discipline positions Holley to create long-term value for our shareholders.”

For more Holley company news, click here.

Forward-Looking Statements 
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are subject to risks, uncertainties, and other important factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including but not limited to Holley’s ability to achieve its stated leverage targets, opportunistically reduce debt, complete accretive acquisitions of complementary brands at attractive valuations, and opportunistically repurchase its own shares, and the other risks and uncertainties set forth in the Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 16, 2026, and in any subsequent filings with the SEC.

About Holley Performance Brands
Holley Performance Brands (NYSE: HLLY) is home to a portfolio of iconic brands that serve enthusiasts across the high-performance aftermarket. The company designs, engineers, manufactures and markets category-leading products and solutions for automotive enthusiasts through a focused portfolio spanning four consumer vertical groupings: American Performance, Modern Truck & Off-Road, Euro & Import, and Safety & Racing. For more than a century, Holley has built its reputation through innovation, technical expertise and a deep understanding of enthusiast culture. For more information, visit https://www.holley.com.

Investor Relations Contact(s):
Anthony Rozmus / Jenna Kozlowski
Solebury Strategic Communications
203-428-3224
Holley@soleburystrat.com

Media Relations Contact(s):
Nathan Espinosa/Michael Murray
Kahn Media
818-881-5246
Holley@KahnMedia.com